EXACT Sciences Corporation

EXACT Sciences — Q2 2024 Earnings Presentation

20 slides from EXACT Sciences's earnings presentation, Jul 31, 2024

  1. Slide 1: Second-quarter 2024 earnings call

    Our purpose is to help eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment. Second-quarter 2024 earnings call July 31, 2024 EXACT SCIENCES 1

  2. Slide 2: Safe harbor and non-GAAP disclosures

    Safe harbor and non-GAAP disclosures This presentation contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are sub

  3. Slide 3: Exact Sciences is a leader in advanced cancer diagnostics

    Exact Sciences is a leader in advanced cancer diagnostics OUR TEAM OUR FLAGSHIP TESTS Q2 RESULTS 500 1M+ Record total revenue of $699M, 13% core revenue growth R&D team members test results in 2Q24 1,350 Record adj. EBITDA of $110M, or 16% margin rate, and free cash flow of $71M person commercial te

  4. Slide 4: Core revenue grew 13% in 2Q24

    Core revenue grew 13% in 2Q24 Core revenue Screening revenue Precision Oncology core revenue $696M $618M +13% $532M $463M +15% $155M $164M +6% 2Q23 2Q24 2Q23 2Q24 2Q23 2Q24 Please refer to our second-quarter 2024 earnings release at exactsciences.com for discussion of non-GAAP financial measures and

  5. Slide 5: Delivered record profitability and strengthened our balance sheet

    Delivered record profitability and strengthened our balance sheet Adjusted EBITDA Free cash flow Adjusted EBITDA margin $110M 15.7% +$43M +500 bps $71M $67M $66M +$5M 10.7% 2Q23 2Q24 2Q23 2Q24 Please refer to our second-quarter 2024 earnings release at exactsciences.com for discussion of non-GAAP fi

  6. Slide 6: Maintaining full-year revenue guidance and raising full-year adjusted EBITDA guidance

    Maintaining full-year revenue guidance and raising full-year adjusted EBITDA guidance Prior guidance July 31 update ∆ at midpoint Total revenue $2.810 - 2.850B $2.810 - 2.850B - Screening $2.155 - 2.175B $2.155 - 2.175B - Precision Oncology $655 - 675M $655 - 675M - Adj. EBITDA $325 - 350M $335 - 35

  7. Slide 7: Cologuard revolutionized colorectal cancer screening and momentum continues to build

    Cologuard revolutionized colorectal cancer screening and momentum continues to build 1M+ Colorectal cancer screening rates U.S. screening eligible population age 50-75 +13 pts. people screened in Q2 2024 20M launch rescreen opportunities with Cologuard patients ages 45-49 100+ care gap program oppor

  8. Slide 8: Key Cologuard growth drivers

    Key Cologuard growth drivers Increasing Cologuard utilization among primary care clinicians Partnering with health systems to address unscreened patients Helping payers improve screening rates and quality metrics Ensuring people remain screened with Cologuard every 3 years Getting 19M unscreened Ame

  9. Slide 9: Using our oncology foundation to increase genomic testing around the world

    Using our oncology foundation to increase genomic testing around the world international adoption 200K+ international patients eligible for Oncotype DX every year ~10%+ +10 pts. 25% increase in international ~30% ordering providers y/y ~20% ASCO® ST. GALLEN NCCN® ESMO NICE included in all major guid

  10. Slide 10: Progress in key pipeline programs with several milestones upcoming

    Progress in key pipeline programs with several milestones upcoming Colon cancer Molecular residual Multi-cancer screening disease screening Generated data supporting Generated colon cancer Authorized by FDA for use in blood-based test validation data 25K person real-world study Expecting Cologuard P

  11. Slide 11: Our purpose is to help eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment

    Our purpose is to help eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment EXACT SCIENCES 11

  12. Slide 12: EXACT SCIENCES

    EXACT SCIENCES 12

  13. Slide 13: Condensed Consolidated Statements of Operations

    EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Condensed Consolidated Statements of Operations (Amounts in thousands, except per share data) Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Revenue $ 699,264 $ 622,093 $ 1,336,788 $ 1,224,543 Operating ex

  14. Slide 14: Condensed Consolidated Balance Sheets

    EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Condensed Consolidated Balance Sheets (Amounts in thousands) December 31, June 30, 2024 2023 Assets Cash and cash equivalents $ 530,180 $ 605,378 Marketable securities 416,602 172,266 Accounts receivable, net 263,865 203,623 Invento

  15. Slide 15: Reconciliation of Core Revenue

    EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Reconciliation of Core Revenue (Amounts in thousands) GAAP Three Months Ended June 30, 2024 2023 % Change Screening $ 531,606 $ 462,787 15 % Precision Oncology 167,658 157,174 7 % COVID-19 Testing — 2,132 (100) % Total $ 699,264 $ 6

  16. Slide 16: Non-GAAP Gross Profit and Non-GAAP Gross Margin Reconciliations

    EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Non-GAAP Gross Profit and Non-GAAP Gross Margin Reconciliations (Amounts in thousands) Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Revenue $ 699,264 $ 622,093 $ 1,336,788 $ 1,224,543 Cost of sales (excl

  17. Slide 17: EBITDA and Adjusted EBITDA Reconciliations

    EXACT SCIENCES CORPORATION Selected Unaudited Financial Information EBITDA and Adjusted EBITDA Reconciliations (Amounts in thousands) Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Net loss $ (15,808) $ (81,026) $ (126,036) $ (155,177) Interest expense (income) (1) (111) 7

  18. Slide 18: Reconciliation of U.S. GAAP to Non-GAAP Measures

    EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Reconciliation of U.S. GAAP to Non-GAAP Measures (Amounts in thousands) Three Months Ended June 30, 2024 Research & General & Amortization of Development Sales & Marketing Administrative acquired intangiible Impairment of Other Oper

  19. Slide 19: Reconciliation of U.S. GAAP to Non-GAAP Measures

    EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Reconciliation of U.S. GAAP to Non-GAAP Measures (Amounts in thousands) Three Months Ended June 30, 2023 Research & General & Amortization of Development Sales & Marketing Administrative acquired intangiible Impairment of Other Oper

  20. Slide 20: Condensed Consolidated Statements of Cash Flows and Reconciliation of Free Cash Flow

    EXACT SCIENCES CORPORATION Selected Unaudited Financial Information Condensed Consolidated Statements of Cash Flows and Reconciliation of Free Cash Flow (Amounts in thousands) Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Net cash provided by operating activities 107,065

Exact Sciences — Q2 2024 Earnings Presentation on 6ix